Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 24, 2021Open Access

Effectiveness of COVID-19 vaccines against the B.1.617.2 variant

View Full Paper
Ask AI
Bookmark
Share

Authors

JBJamie Lopez BernalPublic Health AgencyNANick AndrewsUniversity of LondonCGCharlotte GowerUK Health Security Agency

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bernal et al. (2021) studied this question.

synapsesocial.com/papers/6a98045b161d47660415ee4dhttps://doi.org/10.1101/2021.05.22.21257658
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Neutralizing Activity of BNT162b2-Elicited Serum2021 · 633 citations
  2. 2Data, disease and diplomacy: GISAID's innovative contribution to global health2017 · 2,318 citations
  3. 3Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine2020 · 15,769 citations
  4. 4Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of Long-Term Care Facilities (VIVALDI study)2021 · 34 citations
  5. 5Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees2021 · 234 citations